Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-year persistence of MenACWY-TT immune response in Dutch adolescents
NL-OMON48391Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Jun 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of meningococcal conjugate vaccine GSK 134612 in meningococcal disease (3 cohorts), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Persistence of protective SBA levels at 5 years. Started Jun 2019; status: active, not recruiting.
02
Drugs
meningococcal conjugate vaccine GSK 134612
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NL-OMON48391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48391.